These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15824323)

  • 1. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
    Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
    Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
    J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
    Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
    J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway.
    Matera L; Forno S; Galetto A; Moro F; Garetto S; Mussa A
    Cell Mol Biol Lett; 2007; 12(2):268-79. PubMed ID: 17235439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.
    Signorino E; Brusa D; Granata R; Malavasi F; Ferrone S; Matera L
    Cancer Biol Ther; 2007 Dec; 6(12):1932-7. PubMed ID: 18087220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
    Saito H; Dubsky P; Dantin C; Finn OJ; Banchereau J; Palucka AK
    Breast Cancer Res; 2006; 8(6):R65. PubMed ID: 17129372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
    Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ
    Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.